<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83557">
  <stage>Registered</stage>
  <submitdate>31/01/2009</submitdate>
  <approvaldate>14/08/2009</approvaldate>
  <actrnumber>ACTRN12609000704291</actrnumber>
  <trial_identification>
    <studytitle>A placebo controlled clinical trial on the efficacy of atorvastatin 20 mg daily in patients with bronchial hyper-responsiveness.</studytitle>
    <scientifictitle>A placebo controlled clinical trial on the efficacy of atorvastatin 20 mg daily administration for 4-6 weeks in patients with bronchial hyper-responsiveness.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>bronchial hyper-responsiveness</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Atorvastatin 20mg once daily will be administered orally for 4-6 weeks to all patients in the intervention group according to the clinician's discretion.</interventions>
    <comparator>Identical placebo (sugar pills) made by the same manufacturer once daily for 4 - 6 weeks will be administered to all patients in the control group according to the clinician's discretion.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Decrease in hyperresponsiveness in methacoline challenge test at Baseline and at 4-6 weeks</outcome>
      <timepoint>at Baseline and at 4-6 weeks from the start of the treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Decrease in cough (questionnaire) at Baseline and at 4-6 weeks from the start of the treatment</outcome>
      <timepoint>at Baseline and at 4-6 weeks from the start of the treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>serum IgE (lab test) at Baseline and at 4-6 weeks from the start of the treatment.</outcome>
      <timepoint>at Baseline and at 4-6 weeks from the start of the treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>blood eosinophilia (lab test) at Baseline and at 4-6 weeks from the start of the treatment</outcome>
      <timepoint>at Baseline and at 4-6 weeks from the start of the treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients present with cough for more than 6 weeks.</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients who had contraindication for methacoline challenge test (according to American Thoracic Society/European Respiratory Society -ATS/ERS- guideline 2006)/ patient with previous diagnosis of asthma/patients who suffer heart failure/ obvious paroxysmal nocturnal dyspnea (PND) or wheezing in physical exam.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The treatment allocation was randomized by a researcher who is not directly involved in the trial. Central randomization by telephone.</concealment>
    <sequence>Computerized sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/10/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Shahid Beheshti University, M.C.</primarysponsorname>
    <primarysponsoraddress>Evin Ave., Tehran, 19834</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>National Research Institute for Tuberculosis and Lung Diseases (NRITLD)</fundingname>
      <fundingaddress>Shaheed Bahonar Ave, Darabad 
TEHRAN 19569,P.O: 19575/154</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We could not find any study that has examined the use of atorvastatin in bronchial hyperresponsiveness . The proposed study will provide scientifically valid data to date on whether atorvastatin 20 mg is effective in bronchial hyperresponsiveness or not</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Masih Daneshvari  Research Ethics Committee</ethicname>
      <ethicaddress>Shaheed Bahonar Ave, Darabad, TEHRAN 19569,P.O: 19575/154</ethicaddress>
      <ethicapprovaldate>1/09/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Mohammad Reza Masjedi</name>
      <address>Shaheed Bahonar Ave, Darabad, TEHRAN 19569,P.O: 19575/154</address>
      <phone>+98 21 20109991</phone>
      <fax>+98 21 20109503</fax>
      <email>mrmasjedi@nritld.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Fanak Fahimi, Majid malekmohammad</name>
      <address>Shaheed Bahonar Ave, Darabad, TEHRAN 19569,P.O: 19575/154</address>
      <phone>+98 21 20109503</phone>
      <fax>+98 21 20109503</fax>
      <email>fahimi@nritld.ac.ir                                  fahimi@nritld.ac.ir      mmalekmohammad@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Fanak Fahimi</name>
      <address>Shaheed Bahonar Ave, Darabad, TEHRAN 19569,P.O: 19575/154</address>
      <phone>+982120105050</phone>
      <fax>+98 21 20109503</fax>
      <email>nfayyazi@hums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>